A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
Next-generation incretin therapies, including semaglutide and tirzepatide, have transformed obesity and Type 2 diabetes management. However, evidence-based nutritional strategies to support safe and effective use of these agents remain limited. To ad…
BACKGROUND: Obesity is a complex condition marked by excessive body fat, linked to comorbidities such as type 2 diabetes and cardiovascular disease. Glucagon-like peptide-1 (GLP-1) receptor agonists, initially developed for diabetes, are increasingly…
BACKGROUND AND AIMS: The rising global prevalence of obesity has catalyzed the development of potent glucagon-like peptide-1 (GLP-1) receptor agonists. This narrative review evaluates the efficacy, safety, and practical considerations of injectable s…
BACKGROUND: Obesity is increasingly recognized as a critical modifier of outcomes following transcatheter aortic valve replacement (TAVR), predisposing patients to subclinical leaflet thrombosis (SLT), hypo-attenuated leaflet thickening (HALT), and p…
BACKGROUND: Periodontal ligament stem cells (PDLSCs) hold great promise for periodontal regeneration therapy. However, their self-renewal and multilineage differentiation capabilities are often compromised by adverse factors in the periodontal microe…
BACKGROUND: Menstrual health is a critical marker of physiological and psychological well-being in adolescents. While undernutrition and energy deficiency are well-known causes of menstrual disruption through hypothalamic hypogonadal suppression, the…
BACKGROUND: Tirzepatide, a single-molecule dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor (R) agonist, has shown superiority in the reduction of blood glucose and body weight, above selective GLP-1R a…
INTRODUCTION: In patients with type 2 diabetes mellitus (T2DM), cardiovascular (CV) disease and chronic kidney disease (CKD) drive excess morbidity and mortality. Beyond glucose-lowering, incretin-based therapies may provide organ protection across t…
AIMS: Tirzepatide has demonstrated potent glucose-lowering efficacy and metabolic benefits in subjects with type 2 diabetes (T2D) in Phase III clinical trials. However, its efficacy in real-world clinical practice, particularly among patients receivi…
With rising obesity rates and increasing glucagon-like peptide-1 receptor agonist (GLP-1 RA) use, understanding perinatal prescribing patterns is important. We conducted a retrospective cohort study to examine semaglutide and tirzepatide prescribing…
BACKGROUND: Residual proteinuria remains a major determinant of renal disease progression in Fabry disease (FD) despite optimized enzyme replacement or chaperone therapy and maximal renin-angiotensin system (RAS) blockade. Dual glucose-dependent insu…
INTRODUCTION: Tirzepatide, a glucagon-like peptide-1 receptor agonist (GLP1RA) and glucose-dependent insulinotropic-peptide (GIP), has shown efficacy regarding weight-loss. METHODS: Systematic review and network meta-analysis of randomized controlled…
PURPOSE OF REVIEW: To summarize key findings from cardiovascular disease prevention trials at the 2026 American College of Cardiology (ACC) Conference. RECENT FINDINGS: The Ez-PAVE trial demonstrated that targeting low-density lipoprotein cholesterol…
BACKGROUND: Obesity treatment improves long-term health and quality of life outcomes. Weight reduction and its maintenance play an important role in achieving these goals. We evaluated the efficacy and safety of continuing tirzepatide at the maximum…
Incretins are gut hormones involved in maintaining metabolic homeostasis in the human body, and disorders of the incretin system are recognized as contributing to the pathobiology of metabolic dysfunction and obesity. Incretin polyagonists are transf…
BACKGROUND: Cocaine use disorder (CUD) remains among the most treatment-resistant addictions, characterised by high relapse rates even following extended abstinence periods. Dopamine signalling in mesocorticolimbic circuits contributes to cocaine's r…